SCHEMBL5215696

SCHEMBL5215696

COc1cccc(-n2cc(-c3ccccn3)cn2)n1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.47
PDE10A Q9Y233 2/20 0.43
GRM4 Q14833 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.40
MKNK1 Q9BUB5 3/20 0.39
KDR P35968 3/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TGFBR1 P36897 2/20 0.38
ALKBH2 Q6NS38 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
RAF1 P04049 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217917 0.83 IRAK4 (0.57) GRM5PDE10AGRM4IRAK4KDR
SCHEMBL3921694 0.83 PDE10A (0.51) GRM5PDE10AGRM4IRAK4KDR
SCHEMBL3929725 0.78 GRM5 (0.60) GRM5PDE10AGRM4IRAK4KDR
SCHEMBL5669546 0.77 CYP2A6 (0.59) GRM5PDE10AGRM4KDRMAPT
SCHEMBL30795888 0.75 GRM5 (0.64) GRM5GRM4MKNK1
SCHEMBL3917676 0.75 GRM5 (0.64) GRM5GRM4MKNK1
SCHEMBL16547474 0.75 ALDH1A1 (0.48) PDE10AMAPTKDM4EHTTSMN1; SMN2
SCHEMBL21906552 0.75 GRM5 (0.47) GRM5PDE10AGRM4IRAK4KDR
SCHEMBL31333251 0.74 P2RX7 (0.35) GRM5GRM4MKNK1EGLN1
SCHEMBL5669898 0.74 PDE10A (0.46) GRM5PDE10AGRM4IRAK4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C GRM5 1/4885PDE10A 964/4885GRM4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.